Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Traws Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Traws Pharma's regulatory disclosures and financial reporting.
Traws Pharma, Inc. reported a corporate update highlighting a new antiviral program targeting ongoing Hantavirus and Ebola Virus Disease outbreaks. The company is advancing a proprietary broad-spectrum oral combination that uses a novel “dual-strike” mechanism acting on host cell pathways, with both components already evaluated for safety in prior human studies as single agents. Non-clinical work is underway in validated Hantavirus and Ebola animal models conducted in Biosafety Level 3 and 4 laboratories, while chemical development and manufacturing are being scaled to support rapid deployment and potential stockpiling by health agencies. Traws is also engaging with organizations such as the CDC, Nigeria’s NAFDAC and the African Medicines Agency to support fast-track development and regional access, alongside its existing clinical-stage programs, including tivoxavir marboxil for influenza prevention and treatment and other investigational antivirals like ratutrelvir for COVID‑19.
Traws Pharma, Inc. reported that it may sell additional shares of common stock through its existing at-the-market equity program with Citizens JMP Securities, LLC. Under updated prospectus supplements, the company can offer shares having an aggregate offering price of up to $3,128,399, reflecting its current “baby shelf” limitation under General Instruction I.B.6. of Form S-3.
These sales would occur from time to time under the previously established At The Market Offering Agreement for up to $50,000,000 and rely on the company’s effective shelf registration statement on Form S-3 and related prospectus supplements.
TRAW amended its prospectus supplement to increase its at-the-market (ATM) capacity. Up to $3,128,399 of additional common stock, by aggregate gross sales price, may be offered and sold from time to time under the ATM Agreement with Citizens JMP Securities, LLC.
The supplement states the company previously sold 3,607,270 shares for aggregate gross proceeds of $7,710,729.46 under the ATM Agreement. It reports a $1.62 closing price on May 20, 2026 and cites an aggregate market value of common stock held by non-affiliates of $32,153,972 based on 14,483,771 shares and a March 23, 2026 price of $2.22.
Traws Pharma, Inc. is soliciting proxies for its 2026 virtual Annual Meeting to elect seven directors and ask stockholders to approve several proposals. Key items include a request to amend the 2021 Incentive Compensation Plan to increase the share reserve by 2,000,000 shares, ratify KPMG as auditor, and approve issuance of shares upon exercise of Series B and Series C warrants issued under the Securities Purchase Agreement dated April 15, 2026.
The Board recommends votes "For" the director slate and all proposals. The proxy materials and the Annual Report (including Amendment No. 1) will be made available electronically via the Notice and Access method, and the company intends to file a Form S-8 if the stockholder vote approves the Plan amendment.
Traws Pharma, Inc. files a resale prospectus registering up to 35,897,514 shares of Common Stock for resale by selling stockholders. The shares include 4,993,412 Initial Shares and up to 30,904,102 shares issuable upon exercise of Pre-Funded Warrants and Series A, B and C Warrants. The Company is not selling any shares under this prospectus and will receive no proceeds from resale; however, the Company would receive cash proceeds only if Warrants are exercised for cash. The prospectus notes a beneficial ownership limit on exercises (4.99% or, optionally, 9.99%) and describes warrant exercise conditions tied to regulatory milestones, shareholder approval and registration effectiveness. Shares outstanding were 15,150,669 as of April 24, 2026 as used for the selling-stockholder table.
Traws Pharma, Inc. reports that Perceptive Advisors and related parties hold an aggregate 6.1% stake via 979,815 warrants exercisable into Common Stock. The ownership percentage is calculated using 15,150,669 shares outstanding as of April 24, 2026. The Warrants are exercisable subject to the Beneficial Ownership Limitation, which prevents exercise if doing so would increase beneficial ownership above 9.99%.
Traws Pharma discloses a 6.4% stake held by Squadron Master Fund LP and affiliated filers. The Schedule 13G/A (Amendment No. 3) reports that Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn and William Blank each have shared voting and dispositive power over 511,714 shares.
The filing bases the ownership percentage on 7,990,867 shares outstanding as of November 10, 2025, per the issuer's Form 10-Q. Signatures on the amendment are dated 05/15/2026.
Traws Pharma, Inc. reported a first-quarter 2026 net loss of $7.1 million, reversing net income a year earlier, as it ramped investment in its respiratory virus pipeline. Revenue was zero versus $57,000 in 2025, while research and development spending nearly doubled to $4.9 million, driven by work on ratutrelvir, tivoxavir marboxil and TRX01.
General and administrative costs fell to $2.0 million. Cash and cash equivalents were $3.1 million at March 31, 2026, against an accumulated deficit of $647.1 million and a working capital deficit of $7.9 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without new capital.
In April 2026, Traws closed an equity financing with upfront gross proceeds of $10.0 million and issued milestone-based and common warrants that could raise up to an additional $50.0 million if fully exercised. The company also continued a legal arbitration with a former executive and detailed progress across its clinical programs, including Phase 2 development for ratutrelvir and ongoing regulatory interactions for tivoxavir marboxil.
Traws Pharma, Inc. reported Q1 2026 results showing a net loss of $7.1 million, or $0.53 per basic and diluted share, compared with net income of $21.5 million a year earlier, largely reflecting changes in warrant liability and higher R&D spending.
Revenue was $0.0 million versus $57,000 in Q1 2025. Research and development expense rose to $4.9 million from $2.5 million, while general and administrative expense declined to $2.0 million from $2.8 million.
The company highlighted an up to $60 million private investment in public equity, including $10 million received at closing and additional potential proceeds from milestone-based and three-year warrants, which together with existing cash are expected to fund operations, including a human influenza challenge trial for tivoxavir marboxil, into Q1 2027.